Fate Therapeutics INC 10-Q quarterly reports

Fate Therapeutics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued operational expenses and net losses.

Fate Therapeutics, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing financial results, ongoing clinical development, and risk factors.

Fate Therapeutics reported reduced net losses and operating expenses in its latest quarterly filing, driven by strategic restructuring and ongoing clinical development of its iPSC-derived cell immunotherapies.

Fate Therapeutics announced a reduced net loss for Q2 2025, driven by decreased operating expenses, despite a significant decline in collaboration revenue and a 12% workforce reduction.

Fate Therapeutics announces its Q1 2025 financial results, showing a net loss of $37.6 million and provides updates on its clinical development programs.

Fate Therapeutics' third quarter 2024 report details ongoing clinical trials, financial results, and a collaboration amendment with Ono Pharmaceutical.

Fate Therapeutics reports a net loss of $86.4 million for the first half of 2024, while highlighting advancements in its iPSC-derived cell therapy programs.

Fate Therapeutics' first quarter 2024 results show a net loss, but the company secured significant funding through a public offering and private placement.